12月22日港股通创新药ETF工银(159217)遭净赎回264.88万元

Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF (工银, 159217) experienced net redemptions of 2.6488 million yuan on December 22, 2025, indicating a trend of outflows from this ETF [1] Group 1: Fund Performance - As of December 22, 2025, the latest size of the Hong Kong Stock Connect Innovative Drug ETF (工银, 159217) is 5.1 billion yuan, down from 5.143 billion yuan the previous day, with a net outflow of 0.05% of the previous day's size [1] - Over the past 5 days, the fund has seen net redemptions totaling 2.6403 million yuan, ranking 36th out of 201 in cross-border ETF net outflows [1] - The fund's total size as of December 22, 2025, is 5.1 billion yuan with a total share count of 3.844 billion [1] Group 2: Liquidity and Trading Activity - The cumulative trading amount for the Hong Kong Stock Connect Innovative Drug ETF (工银, 159217) over the last 20 trading days is 9.864 billion yuan, with an average daily trading amount of 493 million yuan [2] - The current fund managers are Liu Weilin and Jiao Wenlong, with returns of 32.68% and 51.22% respectively since their management began [2] Group 3: Holdings and Major Stocks - The fund's major holdings include companies such as BeiGene (百济神州) at 10.84%, CanSino Biologics (康方生物) at 10.77%, and Innovent Biologics (信达生物) at 10.43%, among others [2] - The top holdings by market value include BeiGene with 589 million yuan, CanSino Biologics with 586 million yuan, and Innovent Biologics with 567 million yuan [2] Group 4: Comparative Analysis - Other ETFs tracking the same index include the Huatai-PineBridge Innovative Drug ETF (汇添富国证港股通创新药ETF, 159570) with a size of 22.563 billion yuan and an average daily trading amount of 1.795 billion yuan [2] - The Hong Kong Stock Connect Innovative Drug ETF (工银, 159217) ranks lower in size and trading volume compared to its peers, indicating potential competitive pressures [2]